GSK’s Blenrep receives US FDA approval to treat relapsed/refractory multiple myeloma: London, UK Saturday, October 25, 2025, 11:00 Hrs [IST] GSK plc announced the US Food and Dr ...
The Food and Drug Administration (FDA) has approved Blenrep (belantamab mafodotin-blmf) in combination with bortezomib and dexamethasone for the treatment of adult patients with relapsed or refractory ...
The FDA has approved belantamabmafodotin (Blenrep) in combination with bortezomib (Velcade) and dexamethasone (BVd)for the ...
Investor's Business Daily on MSN
GSK Crumbles As Blood Cancer Comeback Falls Unexpectedly Short
GSK stock crumbled Friday after the FDA granted its blood cancer treatment, Blenrep, a narrower-than-expected approval.
GSK announced FDA’s approval of Blenrep in combination with bortezomib and dexamethasone (BVd) for the treatment of adults diagnosed with relapsed or refractory multiple myeloma who received a minimum ...
Food and Drug Administration has approved British drugmaker GSK's blood cancer drug, Blenrep, in one combination regimen, the ...
The US Food and Drug Administration (FDA) has approved UK pharma major GSK’s Blenrep belantamab mafodotin-blmf) in ...
CURE spoke with Dr. Surbhi Sidana about the recently approved antibody-drug conjugate Blenrep for multiple myeloma.
The FDA approved of Blenrep in combination with bortezomib and dexamethasone (BVd) for adults with relapsed or refractory multiple myeloma who have received at least two prior therapies.
The blue-chip index FTSE 100 rose 0.06% and the British GBP/USD fell 0.2% against the dollar to below 1.33. The DAX index in ...
1don MSN
Health Care Roundup: Market Talk
The latest Market Talks covering the Health Care sector. Published exclusively on Dow Jones Newswires at 4:20 ET, 12:20 ET ...
The FDA approved belantamab mafodotin-blmf in combination with bortezomib and dexamethasone for the treatment of certain ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback